Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01251874

Veliparib and Carboplatin in Treating Women With HER2-Negative MetastaticBreast Cancer

Study identifier: NCT01251874
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Patients must have metastatic or locally advanced inoperable breast cancer that fulfills one of the following two criteria:
    • Triple-negative breast cancer
    • ER and/or PR positive, HER2 negative if their tumors have been shown to be deficient for the FA pathway
    • Her2 negative with a known germline deleterious BRCA1 or BRCA2 mutation
  • Patients with treated brain metastases and life expectancy of greater than 3 months allowed, however, patients with uncontrolled CNS metastasis are not eligible

Type of study:

Phase I

Treatment:

  • 21-day cycles with participants receiving carboplatin intravenously on day one and veliparib orally twice daily on either days 1-7 OR days 1-14

Study sites:

District of Columbia

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington, District of Columbia, 20007
Contact: Claudine Isaacs 202-444-3677 isaacsc@georgetown.edu        

Ohio
Columbus
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State
University Comprehensive Cancer Center
Contact: Bhuvaneswari Ramaswamy 614-293-6401 Bhuvaneswari.Ramaswamy@osumc.edu   

 

Page updated 06/10/13